- 询价
- R&D
- 美国/中国
- xy-38822
- 2025年07月15日
- 科研使用
- Goat，Rabbit，Mouse
- 人，大鼠，小鼠，兔
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 形态：
液态/粉状
- 保存条件：
-20℃保存
- 克隆性：
多克隆
- 标记物：
见说明书
- 适应物种：
人，大鼠，小鼠，兔
- 宿主：
Goat，Rabbit，Mouse
- 应用范围：
科研使用
- 浓度：
1mg/1ml
- 靶点：
来电咨询
- Breast Cancer Resistance Protein (BXP-21) Monoclonal Antibody (SIGNET)详细信息：
-
Description 
Monoclonal antibody against Breast Cancer Resistance Protein (BCRP) Intended Use **Research Use Only (RUO)**
This product is sold for laboratory research use only, not for human or in-vivo use.Clone BXP-21 Form Tissue Culture Supernatant (0.1% NaN3 + 1% BSA) Host Mouse Species Reactivity Breast Cancer Resistance Protein (BXP-21) Monoclonal Antibody (SIGNET)Human IsoType IgG2a Specificity Covances clone BXP-21 reacts with an internal epitope of BCRP a 70kDa membrane transport protein involved in multidrug resistance. Clone BXP-21 does not cross react with the human MDR1, MRP1, and MRP2, gene products.
This antibody was developed using a a fusion protein composed of E. coli maltose binding protein and BCRP peptide [126 amino acids, 271-396 aa of BCRP, GeneBank Accession # AF098951].Uses This antibody is effective in immunohistochemistry (IHC). Suggested Working Dilution The optimal working dilution should be determined for each specific assay condition. - IHC: ≥1:20 for Biotin based detection systems such as USA Ultra Streptavidin Detection (SIG-32250).
Tissue Sections: Formalin-fixed, paraffin-embedded tissues
Pretreatment: For optimal staining, the sections should be pretreated with an antigen unmasking solution such as Citrate Buffer Retrieval Solution (SIG-31932).
Incubation: 30 minutes at room temperature
Storage Breast Cancer Resistance Protein (BXP-21) Monoclonal Antibody (SIGNET) References Minderman H, et al. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry 48(2):59-65.
Maliepaard M, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 61(8):3458-64, 2001.
Kawabata S, et al. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells. Biochem BioPhys Res Commun 280:1216-23, 2001.
Scheffer GL, et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res 60:2589-93, 2000.
Doyle LA, et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 95:15665-15670, 1998.Warranty/Conditions Covance products may not be resold or modified for resale without prior written approval. - IHC: ≥1:20 for Biotin based detection systems such as USA Ultra Streptavidin Detection (SIG-32250).
- Breast Cancer Resistance Protein (BXP-21) Monoclonal Antibody (SIGNET)
- xy-1066R NME1肿瘤抑制基因抗体
xy-1073R Nm23-H2肿瘤抑制基因抗体
xy-0075R Nociceptin孤菲肽/痛敏肽抗体
xy-0129R Nogo R轴索过度生长抑制因子受体/Nogo受体抗体
xy-12151R NAV3神经元引导蛋白3抗体
xy-10027R NCR1细胞毒性受体NK-p46抗体
xy-12146R Neurabin 2神经组织特异性F肌动蛋白结合蛋白2抗体
xy-9320R NYS48NYS48蛋白抗体
xy-9331R NHLRC1肌痉挛性癫痫病相关EPM2蛋白抗体
xy-9332R NHLRC2非霍奇金淋巴瘤重复蛋白2抗体
xy-0323R NMDAR2C谷氨酸受体2C抗体（N端）
xy-6855R NALP4癌/睾丸抗原58抗体
xy-9333R NHLRC3非霍奇金淋巴瘤重复蛋白3抗体
xy-9710R NOP2增殖相关核仁抗原抗体
xy-6864R NALP12NALP12抗体
xy-6865R NALP6富含亮氨酸重复结构域蛋白6抗体
xy-6866R NLRP7富含亮氨酸重复结构域蛋白7抗体
xy-6867R NLRP9富含亮氨酸重复结构域蛋白9抗体
xy-6856R NLRP10富含亮氨酸重复结构域蛋白10抗体
xy-1997R NCX2钠钙交换蛋白2抗体
xy-1998R NDRG2抑癌基因NDRG2抗体
xy-2400R MDC1DNA损伤关卡蛋白1抗体
xy-2401R Nebulin伴肌动蛋白抗体
xy-1999R NDRG4抑癌基因NDRG4抗体
xy-2411R NKG2ANK细胞受体2A抗体
xy-2072R iNOS一氧化氮合成酶-2抗体（诱导型）
xy-1859R NGB脑红蛋白/神经血红蛋白/神经球蛋白抗体
xy-0069R Neurokinin A神经激肽A抗体
xy-3311R Phospho-Numb (Ser276)磷酸化膜相关蛋白Numb抗体
xy-3312R Phospho-NuMA (Ser395)磷酸化核有丝分裂器NuMA蛋白抗体
xy-3512R NuMA核有丝分裂器NuMA蛋白抗体
xy-3510R NUMB膜相关蛋白Numb抗体
xy-3507R NMDAR2A谷氨酸受体2A抗体
xy-3306R Phospho-NMDAR2B (Tyr1070)磷酸化谷氨酸受体2B抗体
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Impact of Breast Cancer Resistance Protein on Cancer Treatment Outcomes
Breast cancer resistance protein (BCRP/ABCG2) was discovered in multidrug resistant breast cancer cells having an ATP-dependent transport-based resistance phenotype. This ABC transporter functions (at least in part) as a xenobiotic protective
In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP)
The organ distribution and substrate specificity of breast cancer resistance protein (BCRP), the product of the human ABCG2 gene, overlaps considerably with that of P-glycoprotein. Both are up-regulated in some cancers, leading to drug
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
技术资料暂无技术资料 索取技术资料
